{
    "Clinical Trial ID": "NCT00068341",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Arm I: HER2+",
        "(Pre-Op TCH)",
        "INTERVENTION 2: ",
        "  Arm II: HER2+",
        "  (Pre-Op TC, Post-Op Herceptin)"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Confirmed infiltrating adenocarcinoma of the breast",
        "  Primary breast cancer > 5cm, or skin/chest wall involvement, any N, without evidence of metastasis.",
        "  No prior radiation to the involved breast",
        "  ECOG (Electrocochleography) performance status 0-2",
        "  Age 18 years to 80 years",
        "  Absolute Neutrophil count > 1500 cell/\u03bcl, platelet count > 100000 cells/\u03bcl and hemoglobin > 9 g/dl",
        "  All liver function tests < upper limit of normal",
        "  Serum creatinine < 2.0 mg/dl",
        "  Normal left ventricular ejection fraction (LVEF) as determined by MUGA (Multiple Gated Acquisition) scan or echocardiogram",
        "  HER-2/neu status is determined by a FISH (Fluorescence in situ hybridization) test. [FISH (+) is HER-2/neu (+)]",
        "  If female of childbearing potential, pregnancy test is negative",
        "  If premenopausal and not surgically sterilized, the patient agrees to use effective birth control method for the duration of the study",
        "  Informed consent has been obtained",
        "Exclusion Criteria:",
        "  Non-confirmed infiltrating adenocarcinoma breast cancer",
        "  Evidence of metastasis",
        "  Previous chemotherapy using the drugs proposed in this study, specifically Herceptin\u00ae, Taxotere\u00ae, and/or Carboplatin",
        "  Prior radiation to the involved breast",
        "  Recent breast cancer drug therapy within last 5 years of any form",
        "  History of allergy to polysorbate or castor oil",
        "  Ongoing active infection",
        "  Concurrent life-limiting disease with a life expectancy of less than one year",
        "  Past or current history of other malignancy within the past 5 years which could affect the diagnosis or assessment of breast cancer, except for curatively treated non-melanoma skin cancer and/or in situ carcinoma of the cervix",
        "  Pregnancy, nursing, fertile women who do not use birth control device",
        "  Inability to give informed consent",
        "  Patients with pre-existing peripheral neuropathy > grade 2"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Evaluate the Objective Response Rate of Patients Treated With Taxotere/Carboplatin With or Without Herceptin Preoperatively.",
        "  Objective response rate of patients treated with Taxotere/carboplatin with or without Herceptin preoperatively. Objective response equals the combination of complete response (CR), partial response (PR) and marginal response (MR).",
        "  Tumor size was assessed by (1) physical examination, (2) mammography and (3) MRI. 5 response groups: complete response (CR), partial response (PR), marginal response (MR), stable disease (SD) & disease progression (DP). Pathologic response assigned into 2 groups: pCR and non-pCR. pCR-no evidence of residual invasive disease in specimen.",
        "  Time frame: 5 years",
        "Results 1: ",
        "  Arm/Group Title: Arm I: HER2+",
        "  Arm/Group Description: (Pre-Op TCH)",
        "  Overall Number of Participants Analyzed: 15",
        "  Measure Type: Number",
        "  Unit of Measure: participants  DFS (Disease Free Survival): 13",
        "  OS (overall survival): 13",
        "Results 2: ",
        "  Arm/Group Title: Arm II: HER2+",
        "  Arm/Group Description: (Pre-Op TC, Post-Op Herceptin)",
        "  Overall Number of Participants Analyzed: 14",
        "  Measure Type: Number",
        "  Unit of Measure: participants  DFS (Disease Free Survival): 8",
        "  OS (overall survival): 11"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 6/15 (40.00%)",
        "  diarrhea and dehydration * 0/15 (0.00%)",
        "  Severe Dehydration * 1/15 (6.67%)",
        "  hypokalemia * 1/15 (6.67%)",
        "  pain, swelling, mastectomy site cellulitis * 0/15 (0.00%)",
        "  death progressive disease * 0/15 (0.00%)",
        "  divetricular abscess * 0/15 (0.00%)",
        "  fever * 1/15 (6.67%)",
        "  febrile neutropenia * 3/15 (20.00%)",
        "  Neutropenia * 0/15 (0.00%)",
        "Adverse Events 2:",
        "  Total: 4/14 (28.57%)",
        "  diarrhea and dehydration * 0/14 (0.00%)",
        "  Severe Dehydration * 0/14 (0.00%)",
        "  hypokalemia * 0/14 (0.00%)",
        "  pain, swelling, mastectomy site cellulitis * 0/14 (0.00%)",
        "  death progressive disease * 1/14 (7.14%)",
        "  divetricular abscess * 0/14 (0.00%)",
        "  fever * 0/14 (0.00%)",
        "  febrile neutropenia * 2/14 (14.29%)",
        "  Neutropenia * 0/14 (0.00%)"
    ]
}